Enhanced Antimalarial Therapy Using Mefloquine and Artesunate in the Treatment of Uncomplicated Plasmodium falciparum| Chapter 5 | New Advances in Medicine and Medical Science Vol. 8

 The current study proposed to investigate hopeful alternative regimens of artesunate-mefloquine with revised efficacy to deal with multidrug resistant P. falciparum. Malaria-accompanying mortality has wonderfully reduced during the last two decades because the introduction of artemisinin-located combination remedy (ACT). Data from the previously written article on the clinical efficiency of the three-day artesunate-mefloquine blend in the Thai-Myanmar borders during 2008-2009 were secondhand for pharmacokinetic-pharmacodynamic (PK/PD) analysis. All subjects were treated with a three-era combination of artesunate-mefloquine. Population PK-PD models were grown. Data from clinical remarks were used to validate the grown models. Based on mefloquine sensitivity, patient adherence, and dependent biomass, simulations of the clinical productiveness of alternative mefloquine regimens were completed activity. The created PK/PD models are well described accompanying data from dispassionate observations. For mefloquine-opposing P. falciparum, a three-day standard menu of artesunate-mefloquine is suitable (>50% efficacy) only when the level of bootlicker sensitivity was < 1.5-fold of the halt level (IC50 < 36 nM). For mefloquine-sensitive deadbeats with IC50 < 23.19 nM (0.96-fold), all procedures provided satisfactory productiveness. In the isolates with IC50 of 24 nM, regime-I is recommended. Curative situation criteria for mefloquine and artesunate were C336h (>408 ng.mL-1) or Cmax/IC50 (>130.1 g.m/M) and Cmax/IC50 (>381.2 g.m/M), individually. A three-day artesunate-mefloquine is suitable for mefloquine-opposing P. falciparum with IC50 of < 36 nM. Efficacy of the shortened dose procedures is satisfactory only when IC50 was < 24 nM.

Author(s) Details:

Teerachat Saeheng,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, 99 moo 18, Phaholyothin Road, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani-12121, Thailand.

Kesara Na-Bangchang,
Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College, 99 moo 18, Phaholyothin Road, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani-12121, Thailand and Drug Discovery and Development Center, Office of Advanced Science and Technology, 99 Moo 18, Phaholyothin Road, Thammasat University (Rangsit Campus), Klongneung, Klongluang District, Pathumthani-12121, Thailand.

Please see the link here: https://stm.bookpi.org/NAMMS-V8/article/view/11073